{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Number of participants who achieved a confirmed best overall response (BOR) of either complete response (CR) or partial response (PR) during treatment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR) is defined as a disappearance of all target and non-target lesions and partial response (PR) is defined as at least a 30% decrease in the sum of diameters of all target lesions.","groups":[{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by in situ hybridization (ISH) and HER2 overexpression by immunohistochemistry (IHC) which includes IHC 2+ or 3+","id":"OG000","title":"Cohort I"},{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by ISH and HER2 IHC 0 or 1+.","id":"OG001","title":"Cohort II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Assessed in participants with available data in the Efficacy Analysis Set.","reportingStatus":"POSTED","timeFrame":"Up to 34 months","title":"Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR)","type":"PRIMARY","unitOfMeasure":"Participants"}